Latest International Sales News

Memphasys will receive an A$3.5 million advance from major shareholder Peters Investments to expand Felix production, inventory and sales capacity as repeat orders emerge across international markets. The funding carries a 12.5% interest rate, potential equity dilution and requires shareholder and ASX approvals before the convertible notes can be issued.

Rua Bioscience delivered a sharp rise in customer revenue and secured a UK agreement expected to generate NZ$10 million over two years. But PwC disclaimed an audit opinion, warning the company may not have enough cash without another capital raise.

Orthocell posts record FY26 revenue growth driven by expanding US and international sales of its collagen medical devices, while investing ahead in manufacturing capacity and product pipeline.

SomnoMed reported a 3% revenue rise to $114.5 million and a 19% EBITDA increase to $10.9 million in FY26, navigating European market headwinds and a CEO transition while launching its Virtus device targeting sleep apnea with bruxism.

Noumi Limited lifted FY26 revenue by 8.8% and adjusted operating EBITDA by 7.6%, driven by Dairy & Nutritionals' strong earnings and strategic investments in Plant-based Milks. The company faces refinancing uncertainty with $610 million convertible notes maturing in May 2027, prompting a proposed acquisition by majority shareholder Arrovest.

Lindian Resources confirms Kangankunde Rare Earths Project remains on track for first production in late 2026, with concurrent progress across construction, mining, and operational readiness. The company is expanding its operational footprint internationally and strengthening its team to support the transition from construction to production.

XRF Scientific reported an 8% revenue increase to $64.4 million and a modest 1% rise in net profit after tax for FY26, underpinned by strong performances in Precious Metals and Capital Equipment divisions and the strategic acquisition of Bruker’s CGA business.

Lark Distilling Co. Ltd grew net sales by 15% in FY26, driven by whisky and international expansion, but posted a $40 million loss after goodwill and inventory impairments.

AVITA Medical posted robust Q2 2026 results with 18% revenue growth, driven by RECELL and supported by Cohealyx and PermeaDerm, and now expects to reach cash flow breakeven by year-end.

Vmoto Limited’s 2Q26 sales soared 156% year-on-year with strong international orders and strategic partnerships, including a global MotoGP deal and a joint venture in Thailand.

Tissue Repair advances its US Phase III chronic wound trial with 100 patients randomised and targets October FDA 510(k) submission. The company reports a robust cash position bolstered by R&D refunds and has cut manufacturing scale-up costs.

Great Divide Mining Ltd has marked a key milestone by starting gold production and dispatching concentrate shipments from its Challenger Gold Mine, while advancing exploration at Coonambula.